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Malignant melanoma (MM) is usually characterized by a poor
prognosis due to its high tendency to develop metastasis.
Considering the small size of most primary lesions, the metastatic
potential of MM is considerably greater than that of other solid
tumours (Schuchter, 1997). Consequently, for MM patients the
5-year disease-free survival is progressively worsening as Clark
level of invasion and Breslow thickness of primary tumours
increase (falling to under 50% for patients with lesions thicker
than 3 mm) (Berwick and Halpern, 1997). 
Melanocytic transformation is thought to occur by sequential
accumulation of genetic alterations. Although most melanomas
seem to directly arise from normal melanocytes, an increasing
number of evidences indicates that (i) MM progress from 
pre-existing melanocytic naevi and (ii) dysplastic naevi may 
be considered as precursors of melanoma (Haluska and 
Hodi, 1998). 
In the pathogenesis of primary MM, silencing of tumour
suppressor genes as well as activation of oncogenes have been
implicated (Healy et al, 1995; Lee et al, 1997). Genetic alterations
have been frequently described for human chromosomes 9p, 1p,
10q, 6q, 11q, and 18q (Peris et al, 1995; Haluska and Hodi, 1998;
Healy et al, 1998). Rearrangements or deletions of the short arm 
of chromosome 9 seem to represent the most common genetic
aberration detected in early stage MM lesions and atypical naevi,
whereas loss of genetic material from other chromosomal loca-
tions might be associated with progression of melanoma (Haluska
and Hodi, 1998; Birindelli et al, 2000). These findings suggest that
mutation of gene(s) within chromosome 9p may occur during the
initial stages of MM tumorigenesis. 
Molecular and cytogenetic investigations have restricted the
candidate region involved in MM pathogenesis to chromosome
9p21 (Fountain et al, 1992). A genetic locus, CDKN, with two
putative tumour suppressor genes, CDKN2A and  CDKN2B
(also known as p16INK4a and p15INK4b, respectively), which encode
specific inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/
CDK6), has been already identified (Kamb et al, 1994a, 1994b).
CDKN2A has been found inactivated by homozygous deletion or
intragenic mutation at high frequency in a diverse range of tumours
and tumour cell lines, including those derived from melanomas
(Nobori et al, 1994; Foulkes et al, 1997; Kumar et al, 1999).
Melanoma-associated mutations of CDKN2B and p19ARF, whose
transcript is derived from an alternative codon reading frame of
CDKN2A, have been only detected in patients with simultaneous
CDKN2A mutations (Flores et al, 1996; Liu et al, 1997). 
Germline mutations of the genes from the CDKN locus 
have been reported in a subset of MM pedigrees. However, no
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http://www.bjcancer.comdisease-associated mutations of CDKN genes have been found in
about half of the melanoma-prone families with evidence of
linkage to 9p21 (Fitzgerald et al, 1996; Bahuau et al, 1998; Soufir
et al, 1998), suggesting that additional locus/i as well as tumour
suppressor gene(s) within this region may be involved in
melanoma pathogenesis. In addition, the very low frequency of
disease-causing alterations (by mutation or inactivation with loss
of expression) of CDKN genes in sporadic MM cases with allelic
losses at 9p21 is again consistent with the presence of other
melanoma susceptibility gene(s) within this chromosomal area
(Gonzalgo et al, 1997; Ruiz et al, 1998; Wagner et al, 1998; Kumar
et al, 1999). 
To further elucidate the role of the 9p21 region in sporadic
melanoma and based on our large collection of MM patients
(Palmieri et al, 1999), we evaluated the genetic changes associated
with the metastatic progression from primary tumour to secondary
lesion. Using microsatellite markers from a 17-cM region within
the 9p21 chromosomal bands, we have compared allelic gains 
and losses (detected as microsatellite instability (MSI) and loss 
of heterozygosity (LOH), respectively) between primary MM
tumours and synchronous or asynchronous metastases obtained
from the same patients. Statistical correlations between genetic
alterations and histopathology or clinical parameters were also
inferred. 
MATERIALS AND METHODS 
Tissue samples and DNA extraction 
Patients with histologically documented diagnosis of malignant
melanoma, whose primary and metastatic tumour samples were
available for genetic analysis, were selected for this study. Disease
stage was recorded as IA, IB, IIA, IIB, III, or IV according to the
American Joint Committee on Cancer (AJCC) guidelines. Clinical
characteristics of MM patients are reported in Table 1. 
A total of 66 paired samples of microdissected primary tumours
and corresponding normal tissues, obtained from patients with
MM, were selected for this study. Among the same patients, 58
metastatic tumour specimens (23 from synchronous and 35 from
asynchronous metastases) were also available for genetic analysis.
Secondary MM site has been classified as regional metastasis (R),
in any regional lymph node(s) or local recurrence (in transit meta-
stasis involving skin or subcutaneous tissue more than 2 cm from
the primary tumour but not beyond the regional lymph nodes), and
distant metastasis (M), in skin or subcutaneous tissue or lymph
node(s) beyond the regional lymph nodes as well as any visceral
metastasis. For 16 patients, we obtained tumour specimens from
both regional and distant metastases (in some cases, from multiple
sites). Pathological review was performed on each case to confirm
the MM diagnosis on both primary and secondary lesions. Disease
status at the time of diagnosis was defined depending on clinical
staging as assessed by medical history, physical examination and
instrumental tests. 
Histopathological classification (including Breslow thickness,
Clark level of invasion, and growth pattern in primary tumour) was
based on the criteria of the World Health Organization. Genomic
DNA was extracted from formalin-fixed paraffin-embedded samples
after microdissection separating tumour tissue from adjacent stroma
by light microscopy. DNA was isolated according to previously
described protocols (Pisano et al, 2000). Control DNA was obtained
from normal adjacent skin of the corresponding patients. 
PCR-based analysis 
Primers used to amplify simple sequence repeat markers were
obtained from Life Technologies (Gaithersburg, MD). 9 marker
lociat 9p21 were investigated for both allelic loss and instability:
D9S162, D9S974, D9S942, D9S1748, D9S171, D9S126, D9S259,
D9S169 and D9S263 (telomeric to centromeric; Figure 1). All
primer sequences were as reported in Genome DataBase (GDB at
http://www.gdb.org). For each marker analysis, polymerase chain
reaction (PCR) was performed using 25–50 ng of DNA, 0.5 µ M of
each specific primer, 1.5 µ M MgCl2, 0.2 µ M dNTPs, 1 pmol of one
primer end-labelled with [γ -32P]ATP, and 1 U AmpliTaq Polymerase
(PerkinElmer, Foster City, CA) under the following conditions: one
cycle of enzyme activation at 94˚C for 2 min, followed by 30 cycles
of denaturation at 94˚C for 30 s, primer annealing at 55–60˚C
(depending on primers) for 1 min, and polymerase extension at 72˚C
for 1 min. All PCR reactions were terminated with a 10-minute
extension at 72˚C. All PCR reactions were performed in a 9600
Thermal cycler (PerkinElmer, Foster City, CA). Final products were
diluted 1:1 in denaturing load buffer (95% formamide, 10 mM
NaOH, 0.05% xylenecyanol FF, and 0.05% bromophenol blue),
denatured at 94˚C for 5 min, and 4 µ l were loaded for elec-
trophoresis on 6% polyacrylamide gels containing 7.0 M urea at
80 W. The gels were dried, and exposed to Hyperfilm MP auto-
radiography film (Amersham) for 16 h at room temperature. 
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Table 1 Patients’ characteristics. Staging was according to the American
Joint Committee on Cancer (AJCC) guidelines. Data refer to (A) time of
diagnosis and (B) time of tumour tissue sampling 
A
Characteristics Number of % 
patients
Total analysed 66
Males/Females 37/29 56/44 
Median age (years) 53
Range 16–84
AJCC stage
I 12 18 
IA/IB 2/10
II 31 47 
IIA/IIB 21/10
III 23 35 
Primary site
Head and neck 8 12 
Limbs 25 38 
Trunk 31 47 
Unknown 2 3 
B
Characteristics Number of % 
patients
AJCC stage
I + II 4 6 
III 48 73 
IV 14 21 
Site of metastasis
Lymph node (LN) 42 64 
LN + skin 9 14 
LN + others 4 6 
Skin 5 7 
Viscerus 2 3 
Status
Dead/alive 21/40 32/61 
Lost in follow-up 5 7 Loss of heterozygosity (LOH) was defined by the absence or at
least two-thirds reduction in the intensity of one allele in the
tumour sample after comparison to the heterozygous normal tissue
genotype (referred to as informative case). LOH scoring was
performed by at least two investigators. Microsatellite instability
(MSI) was defined by the presence of additional bands (due to
deletions or insertions) in the PCR-amplified product derived from
tumour DNA compared with normal DNA. 
Statistical analysis 
Univariate analysis of different variables (presence of LOH and/or
MSI, AJCC stage at the time of diagnosis, number and type of
metastatic sites, primary tumour location, sex, age, and clinical
outcome (disease-free survival and overall survival)) was
performed by Pearson’s Chi-Square test, using the statistical-
package SPSS/7.5 per Windows. 
RESULTS 
Assessment of the genetic alterations at various microsatellite loci
within the chromosome 9p21 was carried out in archival tissues
from 66 patients with sporadic MM. As shown in Table 1A,
majority of MM patients presented localized disease (43/66 at
stages I and II; 65%) at the time of diagnosis, whereas the
remaining of them presented synchronous metastases in regional
lymph node (23/66 at stage III; 35%). Conversely, almost all
patients (62/66; 94%) presented loco-regional recurrences or
distant metastases (with 21 registered deaths; 32%) at the time of
this study (Table 1B); records of clinical follow-up for each patient
were available, covering a median period of 78 months (range
21–172). 
Paraffin-embedded tissues from primary tumours and corre-
sponding metastases were available in 58 MM patients; there-
fore, in 8 cases we only obtained the primary tumour specimens.
Genomic DNAs from paired normal and tumour tissues were
amplified by PCR using 9 highly polymorphic markers for
Genetic alterations at 9p21 in melanoma 1709
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Figure 1 Representative examples of genotyping analysis of primary
melanomas and their metastases. Lanes corresponding to normal and
primary tumour DNA are labelled N and T, respectively. Secondary lesions
are reported as regional metastasis (R) or distant metastasis (M) (see
Materials and Methods). For case 63, M1 and M2 represent distant
metastases at lymph nodal and subcutaneous locations, respectively 
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Figure 2 Genetic alteration map at 9p21. Marker loci are ordered telomeric to centromeric. Genetic position of each marker is indicated in centiMorgans (cM),
as reported in Marshmed map (at: http://www.marshmed.org). Markers spanning the CDKN locus are boxed. Patients are indicated by their number in the
series. Black boxes indicate LOH. Empty white boxes indicate retained heterozygosity. White boxes with O or X indicate constitutional homozygosity or no data,
respectively. Grey boxes indicate microsatellite instability. Patterns of genetic alteration among (A) primary melanomas, and (B) secondary tumours (R and M,
regional and distant metastasis, respectively) microsatellite loci spanning about 17-cM at 9p21: cen-D9S263-
D9S169- D9S259- D9S126- D9S171- D9S1748- D9S942-
D9S974- D9S162-tel. The microsatellite markers D9S1748,
D9S942 and D9S974 are physically positioned within a 50-kb
region spanning the CDKN locus (including the genes
p16/CDKN2A and p15/CDKN2B). Changes in electrophoretic
mobility of the microsatellite markers in tumours, after compar-
ison with corresponding normal DNAs, permitted to define the
genetic profile of primary and metastatic MM lesions at 9p21. In
Figure 1, typical examples of such changes (referred to as loss of
heterozygosity, LOH, and microsatellite instability, MSI) are
presented for cases in which substantially different patterns of
genetic alteration were observed between primary tumours and
their metastases. 
In cases 33 and 63 of Figure 1 (with markers D9S162 and
D9S169, respectively), a complete deletion of one allele was
observed in regional or distant metastases (R or M, respectively;
see Materials and Methods for relative classification) but not in
primary tumours (T), whereas in other two cases, 60 and 55 (with
markers D9S162 and D9S169, respectively), LOH was only
present in distant recurrences. Detection of additional bands, indi-
cating the presence of MSI, in regional metastasis of case 13 (with
marker D9S974) as well as particularly evident rearrangements at
loci D9S942 and D9S126 in regional or distant metastases of cases
11 and 29, respectively (in both cases, allelic loss in R samples and
MSI in M tissues were observed; on this regard, an insertion of
dinucleotide repeats in the retained allele of 29R sample could
explain the presence of a completely new allele in 29 M sample)
are also reported in Figure 1. To avoid any false positive or nega-
tive result due to PCR-based artifacts, all unclear or ambiguous
data were confirmed in replicated experiments (in some cases, also
using different electrophoretic conditions to better separate the
PCR products). 
Overall, analyses of multiple metastatic tumours from the same
patients revealed only a small fraction of cases with LOH detected
exclusively in the secondary MM lesions. In fact, fine deletion
mapping of the 9p21 region using the 9 microsatellite markers
showed minimal differences in patterns of loss and retention
between primary melanomas and their metastases. In Figure 2, all
primary and secondary MM cases with at least one marker
carrying a genetic alteration (LOH or MSI) at 9p21 are reported.
Presence of allelic deletions was revealed in 27 out of 66 primary
tumours (41%), whereas MSI was found in 11/66 (17%) speci-
mens at the same level (Figure 2A). In metastatic tumour samples,
while marker instability (associated or not to allelic losses)
became more prevalent (22/58, 38%), a quite identical pattern of
allelic deletions was observed, except for a slight increase of the
total number of LOH+ cases or the presence of larger deletions in
some regions already affected in primary MM tumours (Figure
2B). In particular, microsatellite analysis of all secondary lesions
from the 36 patients negative for LOH in primary melanomas
revealed 5 new LOH+ cases (11R, 29M, 33R, 60M, and 63R),
bringing the total to 27/58 (47%) secondary tumours with allelic
deletion in at least one locus (Figure 2B). Altogether, genetic alter-
ations at 9p21 (including LOH and/or MSI) were found in 33/66
(50%) primary MM tumours and 39/58 (67%) corresponding
metastatic lesions. 
As summarized in Table 2, two thirds (45/66; 68%) of MM
patients presented 9p21 genetic alterations in at least one sample
(from primary and/or secondary lesions). With the exclusion of the
8 MM cases for whom only tumour samples were available, for
the majority (41/58; 71%) of patients microsatellite analysis was
performed at both primary melanoma and one metastatic site
(regional or distant metastasis) (Table 2). In the remaining 17
cases, multiple metastases from the same patients were analysed
(Table 2), and the 14 MM cases found positive for genetic alter-
ations at 9p21 are shown in Figure 3. 
The observed frequencies of allelic gains and losses for the nine
markers at 9p21 used in this study are reported in Table 3. LOH
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Table 2 Results of microsatellite analysis at 9p21 in primary and secondary
MM lesions. Patients are grouped according to the type of tumour samples
analysed. 9p21+ indicates the presence of 9p21 genetic alterations in at least
one sample (from primary and/or secondary lesions) 
Sample 9p21+
Tumour R / M 
(patients) MSI+ LOH+ MSI+ LOH+ 
T only 5 2 4 ––  
(8)
T + R 23 4 15 12 14 
(37)
T + M 3 0 2 1 2 
(4)
T + R + M 14 5 6 9 11 
(17) 
TOTAL 45 11 27 22 27 
(66) 
T, primary tumour; R, regional metastasis; M, distant metastasis (see
Materials and Methods).
Marker TRMTRMTRMTRMTRMTRMTRMTRMTRMTRMTRMTRMTRMTR
6 1 12 93 35 25 56 06 36 56 87 07 47 68 7
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Figure 3 Results of microsatellite analysis at 9p21 among the 14 patients with multiple metastases. T, primary tumour; R, regional metastasis; M, distant
metastasis (see Materials and Methods). Markers spanning the CDKN locus are boxed. Meaning of boxes and symbols is as in legend of Figure 2 ranged from 9% for both D9S259 and D9S263 to 27% for
D9S171, in primary tumours, and from 12% for D9S974 to 28%
for D9S1748 in secondary MM lesions, with an average of 66%
informativeness at each locus (Table 3A). MSI was detected at
very low levels in primary melanomas (ranging from 1.5% for
D9S171 to 6.3% for D9S259), with an increased incidence in
secondary tumours (ranging from 4% for D9S126 to 12% for
D9S263) (Table 3B). 
The 27 primary tumours with LOH were separately reported in
Figure 4. Most melanomas (20, 74%) presented the involvement of
the markers (D9S1748, D9S942, and D9S974) spanning the
CDKN locus (Fig. 4A). In this group, four cases (70, 76, 102 and
65), showing heterozygosity at loci surrounding the CDKN genes
as well as LOH in the telomeric and centromeric regions bracket-
ing this locus (see Fig. 4A), could represent tumours carrying large
allelic deletions (interspersed heterozygosity has been described as
probably due to the presence of contaminating stromal cells
(Cairns et al, 1995)). 
For 5 of these 20 patients (cases 67, 70, 80, 103 and 105; 
Figure 4A), peripheral blood samples were available and additional
Genetic alterations at 9p21 in melanoma 1711
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Table 3  Frequencies of LOH and MSI for each 9p21 locus marker in primary and secondary
MM lesions. Loci are listed telomeric to centromeric, and the three markers from the CDKN locus
are boxed. (A) LOH frequency is calculated taking into account the number of the informative
samples for each marker. (B) MSI frequency is determined on the basis of the analysed cases 
A 
Primary tumours Secondary lesions 
Marker Informative/ LOH+ LOH Informative/ LOH+ LOH 
Analysed cases cases % Analysed cases cases  % 
D9S162 42/64 5 12 38/56 7 18 
D9S974 47/66 6 13 41/58 5 12 
D9S942 46/66 7 15 40/58 9 23 
D9S1748 48/66 11 23 43/58 12 28 
D9S171 49/66 13 27 44/58 12 27 
D9S126 39/57 6 15 36/53 7 19 
D9S259 44/64 4 9 39/56 6 15 
D9S169 31/57 3 10 28/53 4 14 
D9S263 32/60 3 9 29/52 4 14 
B 
Primary tumours Secondary lesions 
Marker Analysed cases MSI+ MSI Analysed cases MSI+ MSI 
cases % cases % 
D9S162 64 1 1.6 56 3 5 
D9S974 66 2 3.0 58 5 9 
D9S942 66 2 3.0 58 4 7 
D9S1748 66 2 3.0 58 3 5 
D9S171 66 1 1.5 58 4 7 
D9S126 57 1 1.8 53 2 4 
D9S259 64 4 6.3 56 6 11 
D9S169 57 1 1.8 53 4 8 
D9S263 60 3 4.9 52 6 12
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Figure 4 Classification of the 27 LOH+ primary tumours. Patients were grouped according to the presence of allelic deletions involving (A) or not (B) the
markers (boxed) from the CDKN locus. Meaning of boxes and symbols is as in legend of Figure 2specimens from microdissected primary tumours were obtained.
In these cases, direct sequencing of the corresponding genomic
DNAs was performed for exons 1, 2, and 3 of p16/CDKN2A.
Although LOHs were particularly evident within the region of 
the CDKN locus for all 5 primary melanomas analysed (see 
Figure 4A), no somatic or germline mutations were detected in any
of these exons (data not shown). 
Among the remaining 7 (26%) LOH+ primary melanomas,
allelic deletions were found confined to regions centromeric to
CDKN locus (Figure 4B). Interestingly, LOH analysis in this
subset of patients seem to narrow the region of allelic loss to
D9S171, which remained the only deleted marker in three primary
tumours (cases 12, 56 and 107; Figure 4B). Altogether, LOHs at
the locus D9S171 were detected in 13/27 (48%) primary MM
tumours. 
No significant statistical correlations between the presence of
9p21 genetic alterations (LOH and/or MSI) and any histological or
clinical parameter (Breslow, Clark, primary site, number and type
of metastatic sites, sex, age, and clinical outcome) was observed.
After classification by disease stage (following the AJCC guide-
lines), a quite identical distribution was observed among the
groups of MM patients negative (6/12 (50%) stage I, 15/31 (48%)
stage II, and 11/23 (48%) stage III patients) or positive (6/12
(50%) stage I, 16/31 (52%) stage II, and 12/23 (52%) stage III
patients) for genetic alterations at 9p21. With the exclusion of the
5 MM patients lost during the follow-up (see Table 1B), no signi-
ficant differences in disease-free survival (DFS) or overall survival
(OS) rates were observed between the two groups, without (31
patients: median DFS, 21 months; median OS, 43 months) and
with (30 patients: median DFS, 22 months; median OS, 40
months) 9p21 genetic alterations. 
DISCUSSION 
In this study we systematically investigated the genetic profile at
chromosome 9p21 of primary tumours and corresponding meta-
stases in a number of patients with malignant melanoma. Among
66 primary MM lesions, screening with 9 markers covering a
17-cM distance at this chromosomal location allowed to identify a
large subset (27; 41%) of tumours carrying at least one allelic dele-
tion. LOH at one or more polymorphic microsatellite markers on
9p21 has been reported ranging from 20% to 71% in uncultured
sporadic primary melanomas, whereas 63% to 96% of the MM cell
lines have been demonstrated to harbour allelic losses within the
same region (Gonzalgo et al, 1997; Haluska and Hodi, 1998;
Kumar et al, 1999). In our study, detection of 9p21 allelic losses at
quite same rate in primary tumours and corresponding metastases
(41% vs 47%, respectively) and, mostly, the presence of highly
similar patterns of LOH among these lesions suggested that such
genetic alterations may occur before tumour dissemination,
playing a role in the development of melanoma. These findings are
consistent with the view that LOH at 9p21 is an early event in the
pathway of progression to melanoma (Fountain et al, 1992; Healy
et al, 1995; Morita et al, 1998). Nonetheless, the frequency of
allelic loss here reported was lower than that usually found in MM
cell lines, confirming previous data and thus emphasizing the
importance of examining uncultured tumours in order to define all
events involved in tumorigenesis and tumour progression (Ruben
et al, 2000). 
In our series, presence of at least one unstable microsatellite
marker on 9p21 identified a minority of primary MM tumours
(11/66; 17%) with MSI, which may reflect a defect in genes
involved in DNA replication fidelity. Slightly higher frequencies
(ranging from 20% to 26%) have been reported by some authors,
not only in primary melanomas but also in other melanocytic
lesions (including dysplastic and/or common nevi) (Talwalkar et
al, 1998; Birindelli et al, 2000; Ruben et al, 2000). When the same
series of MM patients has been analysed for the presence of
microsatellite instability in the corresponding metastases, we
found a higher incidence (22/58, 38%) of this genetic alteration,
indicating that MSI may probably represent an alternative pathway
of tumour cell evolution in malignant melanoma. 
Overall, comparison of the data on MSI within the 9p21 region
during melanoma progression, as inferred by PCR-based analysis
on either uncultured primary tumours and their metastases or cell
lineages from MM tissues (the latter, characterized by abundant
microsatellite instability (Talwalkar et al, 1998; Birindelli et al,
2000)), strongly suggests the existence of pathogenetic mechan-
isms progressively inducing rearrangements of this chromosomal
area in order to provide a selective advantage during malignant
evolution. In other words, since tumorigenesis and tumour
progression can be considered an evolutionary process, one could
hypothesize that genetic instability at 9p21 may contribute to
selective pressures during melanoma progression. 
Deletion mapping of 9p21 revealed that at least two discrete
regions of allelic loss were present in primary melanomas: the
first, spanning the CDKN locus and including the markers
D9S974, D9S942, and D9S1748 (located in a 50-kb DNA frag-
ment comprising the exons of the genes p16/CDKN2A,
p15/CDKN2B and p19ARF), showed the highest rate of allelic dele-
tions (20/27; 74%); the second, including the marker D9S171
(centromeric to the CDKN locus), was found involved in about
half (13/27; 48%) LOH+ primary tumours, representing the region
of common allelic loss in the 7 (26%) remaining primary
melanomas with LOH not associated to the CDKN locus (see
Figure 4). 
Following the isolation of p16/CDKN2A and p15/CDKN2B,
several studies on a large number of cell lines and primary tumours
have been published, suggesting that this locus may be one of the
most frequently altered in human cancer (Haluska and Hodi,
1998). Studies on melanoma have clearly indicated that
p16/CDKN2A gene is altered in the vast majority of melanoma cell
lines (homozygous deletion rate is roughly 60%; an additional
15% to 20% of lines presents point mutations in the gene, for a
total mutation rate of approximately 75% to 80%) (Flores et al,
1996; Pollock et al, 1996; Foulkes et al, 1997). Conversely, the
rate of p16/CDKN2A alteration is much lower in sporadic uncul-
tured melanomas, ranging from less than 10% in primary tumours
to 20–25% in secondary lesions (Reed et al, 1995; Ruiz et al, 1998;
Fujimoto et al, 1999). This low mutation rate in contrast to a
markedly higher incidence of hemizygous deletions reported for
9p21 in sporadic primary melanomas (20–71% including our
results of 41%; see above) strongly address to search additional
putative tumour suppressor gene(s) within the genomic DNA
regions surrounding the CDKN locus. 
Although presence of a second region of allelic loss that does
not include the CDKN locus has been argued (Merbs and
Sidransky, 1999), several PCR-based LOH studies on melanoma
have indicated some loci lying centromeric or telomeric to the
CDKN genes within the 9p21-p22 chromosomal area (Peris et al,
1995; Ohta et al, 1996; Kumar et al, 1999). The region of allelic
loss spanning the D9S171 locus here identified is consistent with
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deleted in 47% of informative primary melanomas. However, this
region should be further analysed by increasing the marker density
in order to define the minimal genomic segment to be subse-
quently investigated for the presence of candidate gene(s). To date,
additional polymorphic markers across the D9S1748-D9S126
interval are not available in the Genome Database, and thus they
must be developed starting from sequenced DNA (which is now
being reported in public databases). Interestingly, a high frequency
of LOH at 9p21, including the D9S171 locus, has been described
for other types of cancer (Ohgaki et al, 1999; Perinchery et al,
1999), again confirming that this region may harbour several
tumour suppressor genes involved in carcinogenesis. 
Absence of germline or somatic mutations of p16/CDKN2A in
5 MM patients with hemizygous deletions affecting the CDKN
locus could not exclude the presence of intragenic mutations for
the other two genes from the same locus (though p15/CDKN2B
and p19ARF have been usually found mutated in patients with
simultaneous p16/CDKN2A mutations (Flores et al, 1996; Liu et
al, 1997)) or of alternative mechanisms inactivating these genes
on the retained alleles at somatic level. Since a 5′ CpG island
upstream of p16/CDKN2A has been found methylated in several
primary tumours and cell lines (Little and Wainwright, 1995;
Merlo et al, 1995; Costello et al, 1996; Batova et al, 1997), exami-
nation of the methylation status for this gene should be included in
the analysis of uncultured primary and metastatic tumours.
However, data on this regard are lacking also for the difficulty 
in setting adequate protocols for the analysis of small amounts 
of tumour cells from microdissected material. Nonetheless,
melanoma-associated mutations within the promoter regions of the
CDKN genes may also affect their expression by creation of aber-
rant initiation codons, as already demonstrated for p16/CDKN2A
(Liu et al, 1999). 
Altogether, our results on a limited number of MM cases and,
mainly, the findings widely reported suggest that in sporadic
melanoma the inactivation by deletion or mutation or gene
silencing of p16/CDKN2A might be selected during the tumour
progression or, especially, during the establishment and propaga-
tion of MM cells in culture (Healy et al, 1996; Ruben et al, 2000).
As also recently reported (Fujimoto et al, 1999), inactivation of
p16/CDKN2A seems thus not to be as frequent in primary
melanomas as in cell lines. Conversely, in familial melanoma
evidences strongly implicate p16/CDKN2A mutations in deter-
mining predisposition to the disease (Borg et al, 1996; Smith-
Sorenson and Hoving, 1996; Zuo et al, 1996; Platz et al, 1997;
Soufir et al, 1998). 
An additional feature in our series was the presence of few MM
patients (6/58, 10%) showing a discontinuous pattern of genetic
alteration at 9p21 during tumour progression (cases 6, 11, 12, 29,
68, and 74; see Figures 2 and 3). For example, the case 12 at locus
D9S171 (Figure 1) showed LOH in primary tumour and retention
of heterozygosity (thus, no alteration) in its regional metastasis.
Therefore, it appears that in this case at least two independent
subclones have been generated: one lost material at 9p21 and grew
within the primary lesion, whereas the other retained both alleles
but metastasized to regional lymph node. Although these results
have been demonstrated only for a subset of our MM patients, this
could be an indication that in sporadic melanoma (and probably in
other human cancers) the source of tumour cell heterogeneity may
reside in the cell population at the early stage of tumorigenesis.
One could speculate that such heterogeneous population could
evolve independently in the primary melanoma and its metastases,
thus suggesting that a linear progression model may not always
account for the progression of primary tumours to metastases. 
Finally, no genetic alteration at 9p21 (LOH or MSI or both) was
significantly correlated with clinicopathological features (such as
AJCC stage of disease, DFS, or OS) of MM patients in our series.
Univariate analysis only showed a significant association between
disease stage and clinical outcome (particularly for overall
survival, with a median OS of 67 months in stage I, 42 months 
in stage II, and 31 months in stage III patients; P = 0.003), con-
firming the predictive value of clinical stage as prognostic factor.
Therefore, further studies are needed to identify genetic alterations
in primary melanomas which could have clinical relevance as
tumour progression markers. 
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